Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/03/064134
CTRI/2024/03/064134
Not yet recruiting
Phase 3

Effectiveness of biopsychosocial model in the treatment of low back pain - A randomized controlled trial - nil

Ms Vedhika J0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: M625- Muscle wasting and atrophy, not elsewhere classified

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: M625- Muscle wasting and atrophy, not elsewhere classified
Sponsor
Ms Vedhika J
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Ms Vedhika J

Eligibility Criteria

Inclusion Criteria

  • •1\.Subjects with LBP
  • •2\.Duration more than 7 days

Exclusion Criteria

  • •1 Known Inflammatory spinal pathology
  • •2 Lumbar radiculopathy
  • •3 Subjects who had spinal fracture or surgery
  • •4 Have lumbar pain of traumatic origin
  • •5 Have participated in a exercise program in the past three months
  • •6 Have Neurological, Cognitive and psychological problems
  • •7 If they are current or past smokers or tobacco chewers

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A study to learn about the safety and efficacy of CTX001 (the study drug product) to treat beta-thalassemia and severe sickle cell disease in patientsTransfusion-dependent ß-thalassemia (TDT) and severe sickle cell disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040641Term: Sickle cell anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
EUCTR2021-006390-37-DEVertex Pharmaceuticals Incorporated26
Recruiting
Phase 1
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent ß-Thalassemia or Severe Sickle Cell Disease
CTIS2024-514641-12-00Vertex Pharmaceuticals Inc.22
Active, not recruiting
Phase 3
A Phase III Study of ARS-1 Administration in Patients with Food Allegy
JPRN-jRCT2031230143Kenya Morita15
Active, not recruiting
Phase 1
A study to evaluate the effects of Nexium in Children with Erosive Esophagitis (EE)Erosive EsophagitisMedDRA version: 20.1Level: LLTClassification code 10063657Term: Erosive esophagitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2020-002515-21-ESAstraZeneca AB100
Recruiting
Phase 3
Endoscopic evidence of maintenance of healing with oral NEXIUM in patients 1 to 11 years old with erosive esophagitis.
2023-505454-18-00Astrazeneca AB54